Kiniksa publishes corporate presentation on ARCALYST growth in recurrent pericarditis market
PUBT · 1d ago
Share
Listen to the news
- Kiniksa raised 2026 ARCALYST net product sales guidance to USD 930-945 million from USD 900-920 million.
- Q1 2026 ARCALYST net revenue totaled USD 214.3 million, up 56% year over year.
- Cash reserves stood at about USD 468 million in Q1 2026, with operating plan expected to remain cash-flow positive annually.
- KPL-387 Phase 2/3 trial in recurrent pericarditis is enrolling and dosing, with Phase 2 data expected in 2H 2026.
- Company expects to initiate KPL-387 Phase 3 pivotal trial by end of 2026; KPL-1161 Phase 1 first-in-human trial is also slated to start by end of 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kiniksa Pharmaceuticals International plc published the original content used to generate this news brief on April 28, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved